{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 7,
  "pageCount": 45,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Uses a comparative diagram to illustrate the biological mechanism.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/7",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.38,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "image",
      "text": "Comparative diagram of normal vs tumor cell interaction",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9e73b5a-142c-4169-8b90-43709706141b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "E2F is a master regulator of gene expression and Cell Cycle Progression. In human cancers, which consistently have retinoblastoma (Rb) pathway-defective cells, Rb cannot bind to E2F. As a result, Cretostimogene grenadenorepvec is designed to replicate.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2872d141-75e1-4585-8254-06082f78e802",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Laine, et al. Molecular Pathways: Harnessing E2F1 Regulation for Prosenescence Therapy. Molecular Therapy. Vol. 10, No. 4, October 2004.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88b49bba-b7ff-4d99-a4e1-0a90dcfe9781",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2111591-deb4-4c5e-bceb-d8080013a2a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 7,
      "beatId": "1146c958-c0a9-4157-948d-c4acb745bb2f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}